利培酮治疗不同型精神分裂症患者疗效及安全性研究

目的探讨利培酮治疗不同型精神分裂症的疗效及安全性。方法收集100例偏执型及未分化型精神分裂症患者，分别给予利培酮治疗，观察8周，分别于治疗前及治疗第1，2，4，6，8周末分别进行阳性和阴性症状量表（PANSS）、临床总体印象量表、不良反应量表、锥体外系不良反应量表评分，比较不同型精神分裂症患者对利培酮的疗效及不良反应。结果不同型精神分裂症患者治疗后同一时间点PANSS评分比较差异无统计学意义（P〉0．05）；不同型精神分裂症患者同一时间点所用剂量比较差异无统计学意义（P〉0．05）；利培酮治疗前后PANSS评分比较差异有统计学意义（P〈0．01）；入组前体重基线值为（63．91±11．75）kg，治疗8周后为（65．48±10．92）kg，差异有统计学意义（P〈0．01）。结论利培酮对偏执型及未分化型精神分裂症疗效肯定，并具有较好的安全性及耐受性。

Study on efficacy and safety of risperidone in treatment of different kinds of schizophrenia

Objective To explore the safety and efficacy of risperidone in treatment of different kinds of schizophrenia. Methods Collected 100 cases of paranoid and undifferentiated schizophrenia patients, all patients were given risperidone treatment and observed for 8 weeks . Before treatment and at the 1st, 2nd, 4th, 6th, 8th weeks respectively by means of positive and negative symptom scale （PANSS）, the Clinical Global Impression scale, adverse reaction scale, extrapyramidal system adverse reactions to scale score, comparison of different types of schizophrenia patients on risperidone＇ s efficacy and adverse reaction. Results The total PANSS score of different kinds of schizophrenia didn＇ t have great difference （P〉0.05）; the dose also didn＇ t have great statistical difference between different kinds of schizophrenia （P〉0.05）; the total PANSS score had great statistical difference between treatment （P〈O.01）; the group before the baseline weight value was （63.91 ± 11.75） kg, after 8 weeks of treatment it was （65.48 ± 10.92） kg, the difference was statistically significant. Conclusion Risperidone has curative effect on paranoid and undifferentiated schizophrenia, and with good safety and tolerance.